Risk Factors Update Summary
- Barostim indicated for patients with NYHA Class III or II, LVEF ≤ 35%, and NT-proBNP < 1,600 pg/ml.
- Incurred net losses decreased from $42.7 million in 2022 to $39.0 million in 2023.
- Need to enter purchasing contracts with suppliers to meet hospital demands for Barostim.
- Accumulated deficit increased from $436.2 million to $477.4 million.
- Concerns about potential adverse effects of Barostim persist, impacting product reliability.
- Barostim sales growth in the U.S. led to limited product and brand recognition.
- Increased demand for Barostim necessitates additional resources for components, support, and management.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1235912&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.